alexa Long-term Follow-up Of Intravitreal Bevacizumab For The Treatment Of Pediatric Retinal And Choroidal Diseases
ISSN: 2155-9570

Journal of Clinical & Experimental Ophthalmology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

2nd Global Pediatric Ophthalmology Congress
June 05-06, 2017 Milan, Italy

Ronni M Lieberman
Health and Hospitals Corporation, USA
Icahn School of Medicine, USA
ScientificTracks Abstracts: J Clin Exp Ophthalmol
DOI: 10.4172/2155-9570-C1-060
Abstract
The purpose is to describe the long-term outcomes of intravitreal bevacizumab (IVB) for the treatment of pediatric retinal and choroidal diseases. We performed a retrospective analysis of all pediatric patients receiving IVB at our HHC facilities for retinal and choroidal disease. We analyzed the data for visual acuity, stabilization of disease process and central macular thickness for 1 year. Safety data (adverse events) were analyzed. All eyes receiving IVB for the following were included in this analysis: Sickle cell retinopathy, Coats disease, familial exudative vitreoretinopathy (FEVR), SRNM (secondary to trauma, myopia) and CME secondary to uveitis of various etiologies. IVB was used both as a primary treatment and in combination with other options. Patients receiving IVB for ROP were analyzed separately. Patients receiving IVB for pediatric retinal and choroidal disease tolerated the treatment well. Most patients experienced significant improvement or stabilization of vision but long term safety concerns still remains.
Biography

Ronni M Lieberman has received her Medical training at SUNY Downstate in New York, where she also completed her Ophthalmology Residency. She then went on to complete a 2 year Surgical Retina Fellowship at Mount Sinai Medical Center in New York. She is the Director of Medical Retina Services for the Queens Hospital Network, an HHC affiliate. She has published extensively, participated in clinical trials and is involved in the training of ophthalmology residents in the HHC and at Mount Sinai Medical Center.

Email: [email protected]

image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords